The study found that using Veristrat to guide patient therapy decreased the total lifetime direct medical cost per patient by $135.
The company has launched an early-access program for researchers interested in using the system for fractionation of proteomic samples.
OVA2 replaces two of the five OVA1 protein markers with new biomarkers and offers improved specificity and positive predictive value, the company said.
Product revenues, comprised of OVA1 sales, were also flat at $1.5 million, as were licensing revenues at $113,000.
The collaboration is aimed at evaluating new sample stabilization approaches for clinical applications with a focus on imaging mass spectrometry applications.
In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.
Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.
Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.
Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.